홈

규제 업데이트

FDA, EMA, TGA 및 글로벌 규제 동향

#carvedilol ×

UPDATED
규제 업데이트
2026년 9월 25일•1분 읽기
FDA Approves Glenmark’s Carvedilol Generic Tablets (ANDA078251)
The FDA has granted labeling approval for Glenmark Pharmaceuticals’ generic carvedilol tablets (ANDA078251), available in 3.125 mg, 6.25 mg, 12.5 mg and 25 mg oral dosage forms.
UPDATED
규제 업데이트
2026년 9월 25일•1분 읽기
FDA Approves ANDA 077780 for Carvedilol Tablets by TARO
FDA issued an approval letter for ANDA 077780 covering carvedilol oral tablets (3.125 mg, 6.25 mg, 12.5 mg, 25 mg) submitted by TARO; all listed products are marked discontinued.
1
UPDATED
규제 업데이트
2026년 9월 18일•1분 읽기
FDA Approves Carvedilol Generic (ANDA 076649) by Dr. Reddy's Laboratories
FDA granted approval for ANDA 076649, a carvedilol oral tablet generic from Dr. Reddy's Laboratories, covering four strengths and prescription use.
UPDATED
규제 업데이트
2026년 9월 10일•1분 읽기
FDA Approves ANDA078384 for Carvedilol Tablets by Unichem Pharmaceuticals
The FDA has approved ANDA078384 for carvedilol oral tablets (3.125‑25 mg) manufactured by Unichem Pharmaceuticals and sponsored by Regcon Holdings.
UPDATED
규제 업데이트
2026년 8월 30일•1분 읽기
FDA Approves Teva Generic Carvedilol Tablets (ANDA 076373)
The FDA has granted approval for Teva Pharmaceuticals' generic carvedilol oral tablets, covering strengths from 3.125 mg to 25 mg under ANDA 076373.
UPDATED
규제 업데이트
2026년 8월 23일•1분 읽기
Label Mixup Recall: Potential Mislabeling of Famotidine 20 mg Tablets
The FDA reports a labeling mixup where Famotidine 20 mg tablets may be mislabeled as Carvedilol Phosphate ER capsules, along with other products.
1